In the latest trading session, 7.53 million Biocept Inc. (NASDAQ:BIOC) shares changed hands as the company’s beta touched 0.81. With the company’s most recent per share price at $4.35 changing hands around $0.15 or 3.57% at last look, the market valuation stands at $57.16M. BIOC’s current price is a discount, trading about -198.85% off its 52-week high of $13.00. The share price had its 52-week low at $3.46, which suggests the last value was 20.46% up since then. When we look at Biocept Inc.’s average trading volume, we note the 10-day average is 0.17 million shares, with the 3-month average coming to 355.24K.
Analysts gave the Biocept Inc. (BIOC) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BIOC as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Biocept Inc.’s EPS for the current quarter is expected to be $0.
Biocept Inc. (NASDAQ:BIOC) trade information
Instantly BIOC is in green as seen in intraday trades today. With action -8.10%, the performance over the past five days has been red. The jump to weekly highs of 4.95 on Monday, 06/21/21 added 3.57% to the stock’s daily price. The company’s shares are showing year-to-date downside of -5.41%, with the 5-day performance at -8.10% in the red. However, in the 30-day time frame, Biocept Inc. (NASDAQ:BIOC) is -7.49% down. Looking at the short shares, we see there were 0.59 million shares sold at short interest cover period of 3.4 days.
The consensus price target for the stock as assigned by Wall Street analysts is $12.00, meaning bulls need an upside of 63.75% from its recent market value. According to analyst projections, BIOC’s forecast low is $12.00 with $12.00 as the target high. To hit the forecast high, the stock’s price needs a -175.86% plunge from its current level, while the stock would need to soar -175.86% for it to hit the projected low.
Biocept Inc. (BIOC) estimates and forecasts
Year-over-year growth is forecast to reach 36.60% up from the last financial year.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of $17.76 million. 1 analysts are of the opinion that Biocept Inc.’s revenue for the quarter ending Jun 2021 will be $9.74 million. The company’s revenue for the corresponding quarters a year ago was $1.45 million and $917k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 1,127.10%. The estimates for the next quarter sales put growth at 962.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 72.30%. The 2021 estimates are for Biocept Inc. earnings to increase by 87.70%, but the outlook for the next 5-year period is at 40.00% per year.
Biocept Inc. is expected to release its next quarterly earnings report in July.
Biocept Inc. (NASDAQ:BIOC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.05% of Biocept Inc. shares while 10.56% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 10.57%. There are 10.56% institutions holding the Biocept Inc. stock share, with Vanguard Group, Inc. (The) the top institutional holder. As of Mar 30, 2021, the company held 4.98% of the shares, roughly 0.67 million BIOC shares worth $3.4 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 1.43% or 0.19 million shares worth $0.98 million as of Mar 30, 2021.
Among Mutual Funds, the top two as of Mar 30, 2021 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 0.43 million shares estimated at $2.2 million under it, the former controlled 3.23% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.63% of the shares, roughly 0.22 million shares worth around $1.11 million.